Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.62 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3097255 | 0.90 | GRM2 (0.51) | GRM2SCN5ASCN1ASCN2AS1PR1 | |
| SCHEMBL2122976 | 0.88 | GRM2 (0.76) | GRM2SCN5ASCN1ASCN2APLAT | |
| SCHEMBL3092433 | 0.86 | GRM2 (0.45) | GRM2MAPTPKMALDH1A1 | |
| SCHEMBL13180434 | 0.85 | GRM2 (0.63) | GRM2SCN5ASCN1ASCN2AS1PR1 | |
| SCHEMBL2022166 | 0.84 | GRM2 (0.78) | GRM2SCN5ASCN1ASCN2AS1PR1 | |
| SCHEMBL2123539 | 0.84 | GRM2 (0.55) | GRM2SCN5ASCN1ASCN2AS1PR1 | |
| SCHEMBL13042591 | 0.84 | GRM2 (0.55) | GRM2SCN5ASCN1ASCN2AS1PR1 | |
| SCHEMBL2027579 | 0.83 | GRM2 (0.60) | GRM2SCN5ASCN1ASCN2APLAT | |
| SCHEMBL8120477 | 0.83 | GRM2 (0.55) | GRM2SCN5ASCN1ASCN2AS1PR1 | |
| SCHEMBL2124468 | 0.81 | GRM2 (0.66) | GRM2SCN5ASCN1ASCN2AS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
| US-7799792-B2 | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841 | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| US-7799792-B2 | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841 | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| US-7799792-B2 | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841 | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| EP-2167501-A1 | METABOTROPIC GLUTAMATE RECEPTOR OXADIAZOLE LIGANDS AND THEIR USE AS POTENTIATORS - 841 | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008150232-A1 | METABOTROPIC GLUTAMATE RECEPTOR OXADIAZOLE LIGANDS AND THEIR USE AS POTENTIATORS - 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150232-A1 | METABOTROPIC GLUTAMATE RECEPTOR OXADIAZOLE LIGANDS AND THEIR USE AS POTENTIATORS - 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | GRM1, GRM3, GRM2 | GRM2 3/4885SCN5A 1294/4885SCN1A 792/4885 |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | GRM1, GRIN1, GRM3 | GRM2 5/4885SCN5A 1180/4885SCN1A 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.